⌘K

07:00:00·61d

PRReleasevia Quantisnow

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

ByQuantisnow·Wall Street's wire, on your screen.

AGIO· Agios Pharmaceuticals Inc.

Health Care

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

AGIO
Agios Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Apr 20UpdateH.C. Wainwright$50.00
Nov 24UpdateTruist-
Nov 20UpdateLeerink Partners$34.00
Nov 19UpdateRBC Capital Mkts$28.00
Feb 24UpdateH.C. Wainwright$58.00
Oct 16UpdateScotiabank-

Related

SEC3d
SEC Form 10-Q filed by Agios Pharmaceuticals Inc.
SEC3d
Agios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
PR3d
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
SEC7d
SEC Form DEFA14A filed by Agios Pharmaceuticals Inc.
SEC7d
SEC Form DEF 14A filed by Agios Pharmaceuticals Inc.
ANALYST12d
H.C. Wainwright reiterated coverage on Agios Pharma with a new price target
INSIDER25d
SEC Form 4 filed by Burns James William
INSIDER25d
SEC Form 4 filed by Gheuens Sarah